![]() |
市場調查報告書
商品編碼
253943
感染疾病疫苗市場業務聯盟:契約條件、協定內容Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
本報告提供感染疾病相關的各種契約--產業聯盟(夥伴關係)和其他資本交易聯盟--的契約條件的趨勢相關分析、近幾年各種契約趨勢、大規模契約及大型製藥企業的契約概要、契約的種類、開發階段、疾病區分、各技術區分名錄等彙整資料,為您概述為以下內容。
The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies
The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.
This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2015, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a review of the leading Infectious Vaccines deals since 2015. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2015. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2015.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.
Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide. Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials includes:
In Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials, the available deals are listed by:
The Global Infectious Vaccines Partnering Terms and Agreements 2015 to 2022: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 700 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:
Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits: